Microglia‐Related Gene Triggering Receptor Expressed in Myeloid Cells 2 (<i>TREM2</i>) Is Upregulated in the Substantia Nigra of Progressive Supranuclear Palsy
Javier Sánchez‐Ruiz de Gordoa, María Elena Erro, Janire Vicuña‐Urriza, María Victoria Zelaya, Paula Tellechea, Blanca Acha, Sara Zueco, Amaya Urdánoz‐Casado, Miren Roldán, Idoia Blanco‐Luquin, Maite Mendióroz
Abstract
BACKGROUND: The role of the microglia-related gene triggering receptor expressed in myeloid cells 2 (TREM2) in primary tauopathies, such as progressive supranuclear palsy (PSP), still remains unclear. OBJECTIVES: The objective of this study was to profile overall and transcript-specific TREM2 expression levels in the substantia nigra (SN) of PSP patients and controls. METHODS: SN samples from neuropathologically confirmed PSP cases (n = 24) and controls (n = 14) were used to measure TREM2 and TREM2-modulating gene Membrane-spanning 4-domains subfamily A member 4A (MS4A4A) mRNA levels by real-time quantitative polymerase chain reaction. Correlation with hyperphosphorylated tau protein burden was assessed. RESULTS: Overall TREM2 and each of the 3 TREM2 transcripts mRNA levels were significantly increased in the SN of PSP cases versus controls. TREM2 mRNA levels positively correlated with hyperphosphorylated tau burden in SN, specifically in neurons. The MS4A4A gene was also upregulated in PSP patients versus controls. CONCLUSIONS: These results add evidence to the involvement of microglia in the disease process of PSP. These findings support the idea that different tauopathies may share common patterns of deregulation in innate immune molecular pathways. © 2020 International Parkinson and Movement Disorder Society.